MRI is the most widely recommended first-line scan for detecting dementia, offering the best balance of detail, availability, and safety. But “best” depends on what your doctor is looking for. A standard MRI excels at revealing brain shrinkage in the early stages, while specialized PET scans can identify the specific proteins behind Alzheimer’s disease or distinguish between different types of dementia. Most people will start with an MRI, and some will need a PET scan to get a definitive answer.
Why MRI Is the Standard Starting Point
MRI produces highly detailed images of brain structure without any radiation. Its primary job in a dementia workup is measuring whether specific brain regions have shrunk, particularly the hippocampus and surrounding structures in the middle of the temporal lobe. These areas are among the first to deteriorate in Alzheimer’s disease, and MRI can pick up on that shrinkage before symptoms become severe.
The numbers back this up. When researchers use MRI to measure hippocampal volume and compare Alzheimer’s patients to healthy controls, sensitivity reaches 95% and specificity hits 92%. Measuring the surrounding cortex performs similarly, with 90% sensitivity and 94% specificity. These are strong results for a scan that’s widely available, takes roughly 30 to 45 minutes, and doesn’t require an injection of radioactive material.
CT scans can also detect brain shrinkage, and they’re faster and cheaper. But MRI provides significantly better soft-tissue contrast, making it superior for spotting subtle early changes. CT is typically reserved for situations where MRI isn’t an option, such as when a patient has certain metal implants or can’t tolerate the longer scan time.
Amyloid PET Scans: Seeing the Protein Behind Alzheimer’s
While MRI shows structure, amyloid PET scans reveal chemistry. They use a small amount of radioactive tracer that binds to beta-amyloid plaques, one of the two hallmark proteins of Alzheimer’s disease. If those plaques light up on the scan, it confirms that Alzheimer’s pathology is present in the brain.
Amyloid PET is highly sensitive. In studies confirmed by autopsy, it detected Alzheimer’s-level amyloid deposits with 96% sensitivity and 86% specificity. That sensitivity is its greatest strength and also its limitation: amyloid plaques can build up in the brain 15 to 20 years before any symptoms appear, and many people with positive amyloid scans never develop cognitive impairment during their lifetime. So a positive result doesn’t necessarily mean dementia is imminent. It tells you the protein is there, not how soon it will cause problems.
For this reason, amyloid PET is most useful when a doctor suspects Alzheimer’s but the clinical picture is unclear, or when confirming the diagnosis matters for treatment decisions, particularly with newer Alzheimer’s drugs that target amyloid directly.
Tau PET Scans: The Strongest Predictor of Decline
Tau is the second hallmark protein of Alzheimer’s, and unlike amyloid, its spread through the brain tracks closely with the timing and severity of cognitive symptoms. A 2024 study published in JAMA Neurology found that among people with mild cognitive impairment, tau PET was the best stand-alone imaging marker for predicting who would progress to full dementia. It outperformed both amyloid PET and MRI for that specific purpose.
This makes tau PET especially valuable in a narrow but important scenario: when someone has early memory problems and the question isn’t just “is something wrong?” but “how fast is this likely to get worse?” Tau PET isn’t yet widely available in routine clinical settings, but its role is growing as more research confirms its predictive power.
FDG-PET: Telling Dementia Types Apart
FDG-PET measures how actively different brain regions are using glucose, which is essentially a map of brain cell activity. Healthy neurons consume a lot of energy. Damaged or dying neurons consume less. The patterns of reduced activity on an FDG-PET scan act like a fingerprint for different types of dementia.
In Alzheimer’s disease, the back and side portions of the brain (the parietal and temporal lobes) show the most pronounced drop in activity, along with a region called the posterior cingulate. Frontotemporal dementia looks different: the frontal lobes and the front portions of the temporal lobes lose activity instead, which lines up with the behavioral and language symptoms that define that condition. Lewy body dementia often mimics the Alzheimer’s pattern but adds a distinctive drop in activity in the occipital lobes, the brain’s visual processing center. That occipital involvement is highly specific to Lewy body dementia and helps separate it from Alzheimer’s when other clues are ambiguous.
This makes FDG-PET particularly useful when a patient’s symptoms don’t fit neatly into one category, or when distinguishing the type of dementia changes the treatment approach.
DaTscan for Suspected Lewy Body Dementia
When Lewy body dementia is on the table, there’s another specialized scan worth knowing about. A DaTscan uses a radioactive tracer that binds to dopamine-producing neurons, which are specifically damaged in Lewy body disease. It’s the only FDA-approved imaging agent in the U.S. for distinguishing Lewy body dementia from Alzheimer’s.
One helpful clue from standard MRI can also point toward Lewy body dementia: the hippocampus and surrounding temporal lobe structures tend to be relatively preserved compared to what you’d see in Alzheimer’s. So if someone has dementia symptoms but their MRI shows a surprisingly intact temporal lobe, that mismatch itself raises the possibility of Lewy body disease and may prompt a DaTscan or FDG-PET for confirmation.
What the Scans Are Like as a Patient
An MRI takes 30 to 45 minutes. You lie still inside a tube-shaped machine that’s noisy but painless. No injections are needed for a standard structural MRI, though some protocols use a contrast dye. The main challenge for people with cognitive difficulties is staying still for the duration.
PET scans require more preparation. You’ll receive an injection of a radioactive tracer, then wait a specific period (usually 30 to 90 minutes, depending on the tracer) for it to distribute through your brain before the actual imaging begins. The scan itself may involve two or more image acquisitions lasting about five minutes each. Technologists take extra care positioning the head to prevent any movement, using foam supports and rolled towels to keep things stable. For patients who are confused or anxious, staff will typically talk through the process beforehand with both the patient and family members.
Cost and Insurance Coverage
MRI is broadly covered by Medicare and most private insurance when ordered as part of a dementia evaluation. PET scans are a different story. Medicare has historically maintained restrictive coverage policies for FDG-PET in dementia, and amyloid PET coverage has been limited to specific clinical scenarios or research registries. Tau PET remains largely a research tool without standard insurance reimbursement. Out-of-pocket costs for a PET scan can run several thousand dollars without coverage, while an MRI copay is typically much lower.
This cost gap is part of why MRI remains the practical first step. It provides substantial diagnostic information at lower cost and wider availability, and PET scans are added when the clinical question demands the extra molecular detail.
AI-Assisted Brain Volume Analysis
A newer development is FDA-cleared software that uses artificial intelligence to automatically measure brain volumes from a standard MRI. One example is Neurophet’s AQUA AD Plus, which labels brain structures, calculates regional volumes, and identifies specific lesion types relevant to Alzheimer’s evaluation. This kind of software doesn’t replace the scan itself; it makes the MRI data more precise and standardized. Instead of a radiologist eyeballing whether the hippocampus looks small, the software generates exact volume measurements that can be compared against age-matched norms. Several similar tools have received FDA clearance, and their use is gradually becoming part of routine dementia imaging at larger medical centers.
Which Scan You’re Likely to Get
For most people being evaluated for memory problems, the path starts with an MRI. It rules out other causes of cognitive decline (tumors, strokes, fluid buildup) while simultaneously measuring the brain atrophy patterns associated with dementia. If the MRI findings, combined with cognitive testing and clinical history, point clearly to a diagnosis, no further imaging may be needed.
PET scans enter the picture when the diagnosis is uncertain, when distinguishing between dementia types matters for treatment, or when confirming Alzheimer’s pathology is needed before starting a targeted medication. Tau PET currently offers the strongest prediction of who will progress from mild impairment to dementia, but it’s not yet part of standard clinical workflows. Amyloid PET provides the most direct confirmation that Alzheimer’s-specific pathology is present. FDG-PET is the go-to tool for telling different dementia types apart based on their metabolic signatures.
There is no single “best” scan in isolation. The best scan is the one that answers the specific clinical question at that point in your evaluation. But if you’re looking for the single most useful starting point, MRI remains the clear answer.